Key Highlights
- AstraZeneca PLC (LSE:AZN) told the market on 8 September 2026 that the Phase III DeLLphi-305 trial had met its primary endpoint, with Imfinzi combined with Imdelltra delivering what the company described as a statistically significant and highly clinically meaningful improvement in overall survival in first-line extensive-stage small cell lung cancer.
- September alone brought a United States approval for Etcamah in HR-positive breast cancer and a European approval for Enhertu in first-line HER2-positive metastatic breast cancer.
A Survival Result in a Cancer That Rarely Gives One
AstraZeneca PLC (LSE:AZN) told the market on 8 September 2026 that the Phase III DeLLphi-305 trial had met its primary endpoint, with Imfinzi combined with Imdelltra delivering what the company described as a statistically significant and highly clinically meaningful improvement in overall survival in first-line extensive-stage small cell lung cancer.
The trial also met key secondary endpoints, showing improvements in progression-free survival and objective response rate. It was conducted with Amgen, which developed Imdelltra, and randomised 563 patients one-to-one after they had completed induction treatment. That design places the combination in the maintenance phase, the stretch after initial chemotherapy when small cell disease characteristically returns.
Why the Setting Is So Unforgiving
Small cell lung cancer is a minority of lung cancer diagnoses but a disproportionate share of its mortality. It grows fast, spreads early and responds briskly to first chemotherapy before relapsing with grim consistency. AstraZeneca put the scale of the problem at an estimated 195,000 people treated for extensive-stage disease worldwide during 2026, with median overall survival on current standard of care around one year and just 3.6% of patients alive five years after diagnosis.
Imfinzi, the PD-L1 inhibitor durvalumab, is already established alongside platinum-based chemotherapy in this setting. The question DeLLphi-305 asked was whether adding a second, mechanistically different agent during maintenance could extend survival beyond what checkpoint blockade alone achieves.
A Different Class of Drug Moves Earlier
Imdelltra, generically tarlatamab, is a bispecific T-cell engager. Instead of lifting the brakes on the immune system as a checkpoint inhibitor does, it physically tethers a tumour antigen to a T-cell receptor, forcing the immune cell into contact with its target. The class has reshaped treatment in several blood cancers but has proved considerably harder to translate into solid tumours, which makes a positive Phase III readout at an early line of therapy notable well beyond this one indication.
Susan Galbraith, AstraZeneca's executive vice president for oncology haematology research and development, described the data as showing an unprecedented improvement in overall survival for this form of lung cancer. Jacob Sands of the Dana-Farber Cancer Institute, an investigator quoted in the release, called the survival results among the most compelling he had seen in his career.
What the Release Withheld
The announcement reported direction and statistical significance rather than the underlying numbers. Median survival, hazard ratios and the detailed safety picture were not disclosed, and full evaluation will depend on presentation of the dataset and regulatory review. Tolerability is the live question: T-cell engagers carry risks of cytokine release syndrome and neurological toxicity, and whether the regimen can be delivered outside specialist centres will shape how widely it is used.
The commercial split also matters. Imdelltra is Amgen's asset, so AstraZeneca's direct gain runs through Imfinzi volumes rather than through the engager itself.
The Wider Financial Picture
The readout lands on a group already reporting momentum. Half-year results published on 27 July 2026 showed total Revenue of $30,672m, up 9% at actual rates and 6% at constant currency, with product sales of $28,896m. Core Earnings Per Share reached $5.21, up 12%, against reported earnings per share of $3.60 and operating profit of $7,410m. The board declared an Interim Dividend of $1.06 per share, equivalent to 79.5 pence or 10.32 Swedish krona.
Guidance for the full year was for mid-to-high single-digit percentage total revenue growth and low double-digit core earnings per share growth. Chief executive Pascal Soriot pointed to six key positive Phase III programmes and eight first approvals in major markets during the period.
What Comes Next
September alone brought a United States approval for Etcamah in HR-positive breast cancer and a European approval for Enhertu in first-line HER2-positive metastatic breast cancer. For DeLLphi-305, the markers are the full data presentation, regulatory submissions, and whether the safety profile supports use outside specialist centres.






Please wait processing your request...